Digital Edition: Market Pathways March 2024

article image

Lightstone Ventures’ Mike Carusi was a trailblazer among investors in prioritizing reimbursement for device start-ups. He talks about the history of that effort and about the current hot-button issue in reimbursement, TCET. European medtechs face challenges in reconciling Europe’s new AI Act with MDR/IVDR requirements; EPA’s final EtO emission rule factors in industry concerns about device shortages; Communicating the value of the regulatory specialist's role to the corporate bottom line.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: